RxDoctor Payments Data

Federico Azpurua, MD

Interventional Cardiology · McAllen, TXNPI 1417116500

Payments from drug & device makers

$19,614in general payments, 2019–2025

Across 229 payments — averaging $85.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$11K
  • Medtronic$4K
  • Abbott$1K
  • Abiomed$943
  • Shockwave Medical, Inc$561
  • Boston Scientific$441
  • plus $2K from 14 others

What the payments were for

  • Consulting fees$4302%
  • Speaking & faculty fees$3,50018%
  • Travel & lodging$7,15736%
  • Food & beverage$8,42943%
  • Education$991%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,614 in reported general payments places this provider in the 65th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$118,391
Medicare patients
407
Services billed
1,134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban192$202,663
EntrestoSacubitril/Valsartan145$188,226
FarxigaDapagliflozin Propanediol114$91,561
XareltoRivaroxaban50$67,251
BrilintaTicagrelor45$35,220
JardianceEmpagliflozin12$15,808
Ranolazine ErRanolazine73$10,398
Amiodarone Hcl33$4,466
Metoprolol Succinate188$2,828
Rosuvastatin Calcium98$2,105
ClopidogrelClopidogrel Bisulfate138$2,009
Atorvastatin Calcium167$1,508
Valsartan72$1,473
Ezetimibe41$1,266
Labetalol Hcl38$1,177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$236$202,663192 claims
NovartisEntresto$206$188,226145 claims
AstraZenecaFarxiga, Brilinta$366$126,782159 claims
Johnson & JohnsonXarelto$49$67,25150 claims
Boehringer IngelheimJardiance$136$15,80812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →